56352-76-2

Upstream product

• 553-53-7 Nicotinic acid hydrazide 
• 98-88-4 benzoyl chloride 
• 614-18-6 3-pyridinecarboxylic acid ethyl ester 
• 10400-19-8 3-pyridinecarbonyl chloride 
• 613-94-5 benzoic acid hydrazide 
• 59-67-6 nicotinic acid 

Downstream Products

• 15311-10-1 2-phenyl-5-(pyridine-3-yl)-1,3,4-thiadiazole 
• 1156534-43-8 2-phenyl-5-(pyridin-3-yl)-1,3,4-selenadiazole 
• 21398-08-3 3-(5-phenyl-1,3,4-oxadiazol-2-yl)pyridine 

Relevant academic research and scientific papers

Synthesis and in vitro urease inhibitory activity of benzohydrazide derivatives, in silico and kinetic studies

Benzohydrazide derivatives 1–43 were synthesized via “one-pot” reaction and structural characterization of these synthetic derivatives was carried out by different spectroscopic techniques such as 1H NMR and EI-MS. The synthetic molecules were evaluated for their in vitro urease inhibitory activity. All synthetic derivatives showed good inhibitory activities in the range of (IC50 = 0.87 ± 0.31–19.0 ± 0.25 μM) as compared to the standard thiourea (IC50 = 21.25 ± 0.15 μM), except seven compounds 17, 18, 23, 24, 29, 30, and 41 which were found to be inactive. The most active compound of the series was compound 36 (IC50 = 0.87 ± 0.31 μM) having two chloro groups at meta positions of ring A and methoxy group at para position of ring B. The structure–activity relationship (SAR) of the active compounds was established on the basis of different substituents and their positions in the molecules. Kinetic studies of the active compounds revealed that compounds can inhibit enzyme via competitive and noncompetitive modes. In silico study was also performed to understand the binding interactions of the molecules (ligand) with the active site of enzyme.

Oxadiazoles in medicinal chemistry

Oxadiazoles are five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom, and they exist in different regioisomeric forms. Oxadiazoles are frequently occurring motifs in druglike molecules, and they are often used with the intention of being bioisosteric replacements for ester and amide functionalities. The current study presents a systematic comparison of 1,2,4- and 1,3,4-oxadiazole matched pairs in the AstraZeneca compound collection. In virtually all cases, the 1,3,4-oxadiazole isomer shows an order of magnitude lower lipophilicity (log D), as compared to its isomeric partner. Significant differences are also observed with respect to metabolic stability, hERG inhibition, and aqueous solubil ity, favoring the 1,3,4-oxadiazole isomers. The difference in profile between the 1,2,4 and 1,3,4 regioisomers can be rationalized by their intrinsically different charge distributions (e.g., dipole moments). To facilitate the use of these heteroaromatic rings, novel synthetic routes for ready access of a broad spectrum of 1,3,4-oxadiazoles, under mild conditions, are described.

Mild and convenient one-pot synthesis of 1,3,4-oxadiazoles

A mild, general, convenient, and efficient one-pot synthesis of 2-phenyl-5-substituted-1,3,4-oxadiazoles is described. Both (hetero)aryl and alkyl carboxylic acids were efficiently condensed with benzohydrazide in the presence of TBTU to give diacylhydrazine intermediates. The latter underwent a smooth TsCl-mediated cyclodehydration reaction to afford 2-phenyl-5-substituted- 1,3,4-oxadiazoles in good to very good yields.

Facile synthesis and stracture of novel 2,5-disubstituted 1,3,4-selenadiazoles

The reaction of hydrazide with carbony] chloride in the presence of sodium carbonates leads to the corresponding 1,2- diacylhydrazines [1a-t, R 1C(O)NHNHC(O)R2, R1 = aryl, R2 = aryl or alkyl] in moderate to excellent yield (57-90%). The latter reacts with 2,4-diphenyl-l,3-diselenadiphosphetane- 2,4-diselenide (Woollins' reagent, WR) in refluxing toluene to give a series of new 2,5-disubstituted 1,3,4-selenadiazoles (2a-t, 51-99% yield). All compounds were characterized spectroscopically and six compounds were characterized crystalloqraphically. Wiley-VCH Verlag GmbH & Co. KGaA.

Synthesis and characterization of new blue-greenish electroluminescent materials based on 1,3,4-oxadiazole-triazolopyridinone hybrids

New functionalized oxadiazole-triazolopyridinone derivatives were synthesized via arcycloaddition. With the chromophores of triazolopyridinone, the photoluminescence spectra of these compounds in dichloromethane solution showed emission peaks between 430 and 520 nm. Following the spectroscopic studies, and the measurements of cyclic voltammogram, 1,3,4-oxadiazole- triazolopyridinone hybrids possess a great potential as highly efficient, blue-greenish, organic light-emitting devices materials.

Compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof

Novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular and neurovascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, inflammatory disorders, immunological disorders, oxidative stress, dermatological disorders and discoloration of teeth, by breaking preformed AGE, of the general formula I, or pharmaceutically acceptable salts thereof, wherein, R1, R2, R3, X and m are as defined in the specification. Also disclosed is a method for preparation of the compounds of general formula (I) and pharmaceutical composition containing one or more compounds as defined above as active ingredients. Also disclosed is a method of treatment of a diabetic patient by administering the compounds as defined above, either singly or in combination with drugs for antidiabetic therapy.